MAP2K7 and melanoma: Pathria et al. [61] demonstrated that concomitant inhibition of AURKA/MEK might overcome resistance in NRAS-mutated melanomas, and Posch et al. [62] reported that combination of MEK and PLK1 inhibitors suppresses proliferation of NRAS mutant melanoma cells in vitro and in vivo.